MedTrace Logo

Carotegrast Methyl in Ulcerative Colitis

NCT06897150 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-02

No results posted yet for this study

Summary

Carotegrast methyl, an oral α4-integrin inhibitor, was recently approved in Japan for the treatment of active ulcerative colitis (UC). However, real-world data regarding its efficacy and safety remain scarce. This study aimed to assess the clinical effectiveness and safety profile of carotegrast methyl in patients with active UC.

Conditions

Interventions

DRUG

Carotegrast methyl

a dosage of 960 mg three times daily

Sponsors & Collaborators

  • Takayuki Yamamoto

    lead OTHER

Principal Investigators

  • Takayuki Yamamoto, MD, PhD · Yokkaichi Hazu Medical Center

  • Takayuki Yamamoto, MD, PhD · Yokkaichi Hazu Medical Center

  • Takayuki Yamamoto, MD, PhD · Yokkaichi Hazu Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2025-03-15
Completion
2025-03-15

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06897150 on ClinicalTrials.gov